Citations

Showing 10 of 108083 citations.

Should Vital Signs be Routinely Obtained Prior to Intravenous Chemotherapy? Results from a 2-Center Study
Menon, Smitha, Foster, Nathan R. , Looker, Sherry, Sorgatz, Kristine, Jatoi, Aminah , Kasi, Pashtoon Murtaza , McWilliams, Robert R.

Mayo Clinic

Cancer Control | August 30, 2017 | Volume: 22 | Issue: 4 | Pages: 515-519

10.1177/107327481502200419 | PMID 26678980 Get It

Spinal Tumor Surgery: Management and the Avoidance of Complications
Clarke, Michelle J. , Vrionis, Frank D.

Mayo Clinic

Cancer Control | August 30, 2017 | Volume: 21 | Issue: 2 | Pages: 124-132

10.1177/107327481402100204 | PMID 24667398 Get It

Background Complication avoidance is paramount to the success of any surgical procedure. In the case of spine tumor surgery, the risk of complications is increased because of the primary disease process and the radiotherapy and chemotherapeutics used to treat the disease. If complications do occur, then life-saving adjuvant treatment must be delayed or withheld until the issue is resolved, potentially impacting overall disease control. Methods We reviewed the literature and our own best practices to provide recommendations on complication avoidance as well as the management of complications that may occur. Appropriate workup of suspected complications and treatment algorithms are also discussed. Results Appropriate patient selection and a multidisciplinary workup are imperative in the setting of spinal tumors. Intraoperative complications may be avoided by employing proper surgical technique and an understanding of the pathological changes in anatomy. Major postoperative issues include wound complications and spinal reconstruction failure. Preoperative surgical planning must include postoperative reconstruction. Patients undergoing spinal tumor resection should be closely monitored for local tumor recurrence, recurrence along the biopsy tract, and for distant metastatic disease. Any suspected recurrence should be closely watched, biopsied if necessary, and promptly treated. Conclusions Because patients with spinal tumors are normally treated with a multidisciplinary approach, emphasis should be placed on the recognition of surgical complications beyond the surgical setting.
Primary Spine Tumors: Diagnosis and Treatment
Mendel, Ehud , Clarke, Michelle J. , Vrionis, Frank D.

Mayo Clinic

Cancer Control | August 30, 2017 | Volume: 21 | Issue: 2 | Pages: 114-123

10.1177/107327481402100203 | PMID 24667397 Get It

Background Primary tumors are rare and those localized to a single location offer the potential for cure. To achieve this, early recognition of the primary tumor and proper workup and treatment are essential. Methods The authors reviewed the literature and best practices to provide recommendations on primary spine tumor treatment. Appropriate workup of primary spine tumors and treatment algorithms are also discussed. Results Patients suspected of a primary spine tumor should undergo fine-needle aspirate biopsy following consultation with the surgical team to ensure the biopsy tract is surgically resectable should the need arise. Once pathology is confirmed, metastatic workup should be performed to guide the level of treatment. If a localized lesion with poor radiation and chemotherapeutic response is diagnosed, then en bloc resection may be required for cure. If en bloc resection is not feasible or metastatic lesions are present, then radiation and medical oncology specialists must work in conjunction with the surgical team to determine the best treatment options. Conclusions Patients with suspected primary tumors of the spine should be treated in a multidisciplinary fashion from the outset. With thoughtful management, these lesions offer the opportunity for surgical cure.
Biology of the Transition of Monoclonal Gammopathy of Undetermined Significance (MGUS) to Multiple Myeloma
Lust, John A., Donovan, Kathleen A., Lust, JA

Mayo Clinic

Cancer Control | August 30, 2017 | Volume: 5 | Issue: 3 | Pages: 209-217

10.1177/107327489800500301 | PMID 10761054 Get It

Background Approximately 25% of patients with monoclonal gammopathy of undetermined significance (MGUS) eventually develop multiple myeloma (MM) or a related plasma cell disorder that is universally fatal. In this report, we examine the changes that occur in the clonal plasma cell that are likely to be important in the progression of MGUS to active myeloma. Methods Studies that investigate the mechanisms involved in the multistep pathogenesis of monoclonal gammopathies are reviewed. Cytokines such as IL- 6 and IL-1β, adhesion molecules, viruses, and oncogenes including ras, bcl-2, Rb, and p53 are discussed. Results IL-1β is produced by plasma cells from virtually all MM patients but is undetectable in most MGUS patients. IL-1β has potent osteoclast activating factor activity, can increase the expression of adhesion molecules, and can induce paracrine IL-6 production. The increased production of adhesion molecules could explain why myeloma cells are found predominantly in the bone marrow. Subsequently, these “fixed” monoclonal plasma cells could now stimulate osteoclasts through the production of IL-1β and paracrine generation of IL-6 resulting in osteolytic disease. With continued progression of the myeloma, the monoclonal plasma cells may later acquire the ability to produce IL-6 in an autocrine fashion that will be manifested clinically by an elevated labeling index. Conclusions A better understanding of the progression of MGUS to myeloma may lead to novel therapeutic strategies to prevent the development of MM.
Progress in the Systemic Treatment of Advanced Soft-Tissue Sarcomas
Okuno, Scott H. , Edmonson, John H.

Mayo Clinic

Cancer Control | August 30, 2017 | Volume: 5 | Issue: 1 | Pages: 1-5

10.1177/107327489800500104 Get It

Background: Despite the plethora of chemotherapeutic remedies for advanced soft-tissue sarcomas, little evidence has developed to indicate that these efforts have been curative. No controlled comparison has yet proven that patients receiving multidrug regimens survive longer than those receiving doxorubicin alone. Methods: The authors review current systemic treatments and then discuss some investigational efforts now in progress. Also, they seek to demonstrate how the therapies currently available can be integrated with surgery and radiation therapy to accomplish more than might be anticipated from chemotherapy alone. Results: While working to develop better systemic therapies for advanced soft-tissue sarcomas, the integrated use of our best chemotherapy regimens in combination with selected surgical and radiotherapy efforts may provide patients with the best available therapy. Some recent observations involving the use of molgramostim plus chemotherapy have been intriguing. Conclusions: Progress in the systemic treatment of advanced soft-tissue sarcomas may be gradual, but it is real. Our daily challenge is to be certain that we offer each patient the best available multimodality treatment applicable to his or her clinical situation. Molgramostim should be made available for further study with chemotherapy in controlled clinical trials.
HER-2 as a Prognostic, Predictive, and Therapeutic Target in Breast Cancer
Perez, Edith A.

Mayo Clinic

Cancer Control | August 30, 2017 | Volume: 6 | Issue: 3 | Pages: 233-240

10.1177/107327489900600301 | PMID 10758552 Get It

Background: An expanded understanding of the biology of breast cancer has led to the identification of the HER-2 receptor as an important growth factor. This receptor possesses intrinsic tyrosine kinase activity and has been associated with aggressive biological behavior and poor clinical outcome. Methods: Data have been reviewed regarding the role of HER-2 expression as a prognostic variable, as a predictive factor for response to chemotherapy and hormonal therapies, and as a directed therapeutic target for breast cancer. Results: Therapy with a humanized monoclonal antibody to HER-2 (trastuzumab) can be effective treatment in some patients with metastatic breast cancer, either given alone or in combination with some chemotherapeutic agents. Cardiac toxicity limits concurrent use with anthracyclines. Clinical trials will further define optimal combination regimens with this agent, and its value in patients with localized or locally advanced stages. Conclusions: Trastuzumab is a significant addition to the armamentarium against breast cancer. Standardization of the optimal method to evaluate for HER-2 overexpression is necessary to better define its role as a prognostic, predictor, and therapeutic target in this disease.
Routes of Opioid Analgesic Therapy in the Management of Cancer Pain
Stevens, Rom A., Ghazi, Salim M.

Mayo Clinic

Cancer Control | August 30, 2017 | Volume: 7 | Issue: 2 | Pages: 132-141

10.1177/107327480000700203 | PMID 10783817 Get It

Prognostic Indicators in Differentiated Thyroid Carcinoma
Dean, Diana S., Hay, Ian

Mayo Clinic

Cancer Control | August 30, 2017 | Volume: 7 | Issue: 3 | Pages: 229-239

10.1177/107327480000700302 | PMID 10832109 Get It

Background Thyroid cancer ranges from well-differentiated lesions with an excellent prognosis to anaplastic carcinoma, which is almost uniformly fatal. Thus, methods to assess the behavior of thyroid malignancies are necessary to arrive at appropriate treatment decisions. Methods We discuss the factors that affect the prognosis of patients with well-differentiated thyroid malignancies, including papillary, follicular, Hürthle cell, and medullary thyroid carcinomas. We also review the presentation, therapy, and outcome of patients seen at our center over a span of 50 years. These data have identified those prognostic factors that are predictive of survival and recurrence in differentiated thyroid cancer. Results Several classifications with different variables have been developed to define risk-group categories. Three widely used systems, in addition to the TNM staging system, include AGES, AMES, and MACIS. Conclusions A better understanding of independently important prognostic variables will result in improved patient care and treatment.
Carcinoid Heart Disease: Medical and Surgical Considerations
Connolly, Heidi M.

Mayo Clinic

Cancer Control | August 30, 2017 | Volume: 8 | Issue: 5 | Pages: 454-460

10.1177/107327480100800511 | PMID 11579342 Get It